This release was issued under a previous government.
Premier Hancock and Minister Horne with Alberta's BIO 2014 delegation
“Alberta has an international reputation for excellence in life sciences research and commercializing new knowledge. We come to BIO to tell the world’s leading pharmaceutical and biotechnology companies why Alberta’s innovation ecosystem can be their competitive advantage.”
"The BIO International Convention will give us the opportunity to meet with companies from the sector and encourage them to invest their resources in our province. We need research and development in biotechnology and healthcare in order to provide Albertans with high quality, leading edge healthcare."
More than 2,500 of the world’s leading life sciences firms from more than 60 countries will gain exposure to Alberta’s life sciences capabilities, talent and opportunities at BIO 2014 in San Diego, California. Past attendance at BIO supported research collaborations and investment in Alberta and formal agreements with multinational pharmaceutical corporations. These partnerships are supporting local innovators and companies.
Past initiatives from Alberta attendance at the BIO International Convention:
- A meeting at BIO in 2010 and subsequent meetings at BIO have resulted in partnerships and investments from Johnson & Johnson (J&J), including:
- a Memorandum of Understanding with J&J Corporate Office of Science and Technology led to a contribution of $1.05 million from the company to explore new technologies in drug discovery in collaboration with the province of British Columbia and Centre for Drug Research and Development and Western Economic Diversification; and,
- Janssen Pharmaceutical Canada Inc., the Canadian arm of J&J, invested into a $600,000 co-managed fund with Alberta and the Alberta Diabetes Foundation to advance diabetes research.
- A Memorandum of Understanding with Pfizer Canada Inc. established the Alberta – Pfizer Translational Research Collaboration, which provided a total of $3.25 million in total funding.
- The $1.475 million, Alberta/Lilly Translational Research Collaboration Fund was established with Lily contributing $975,000 to support health research at publicly funded Alberta post-secondary institutions.
- A Memorandum Of Understanding with Novartis Pharmaceutical Canada Inc. has led to discussion on collaboration opportunities to develop human and animal health therapies. Novartis has also invested $1.2 million in MS research in Alberta.
- A meeting with Gangwon province representatives resulted in support for Alberta researchers and companies working together to develop a breast cancer diagnostic test.
Under the Building Alberta Plan, our government is investing in families and communities, living within our means, and opening new markets for Alberta's resources to ensure we're able to fund the services Albertans told us matter most to them. We will continue to deliver the responsible change Albertans voted for.
NOTE: Premier Hancock and Cabinet are closely monitoring the rainfall levels and flooding situation in southern Alberta. Should conditions worsen; the Premier and Minister Horne will stay in Alberta to lead government’s response and work with any affected communities.
Backgrounder
Itineraries for Premier Hancock and Minister Horne
Itinerary for Premier Hancock*
The estimated cost for travel, accommodation and meals for Premier Hancock and one staff member is $6,361.00.
|
June 21 |
|
|
June 22 |
|
|
June 23 |
|
|
June 24 |
|
|
June 25 |
|
|
June 26 |
|
*Itinerary subject to change.
Itinerary for Minister Horne*
The estimated cost for travel, accommodation and meals for Horne and one staff member is $6,710.50
|
June 21 |
|
|
June 22 |
|
|
June 23 |
|
|
June 24 |
|
|
June 25 |
|
|
June 26 |
|
*Itinerary subject to change.